Sichuan Biokin Pharmaceutical Co., Ltd. Class ASSE: 688506

(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Inclusion of iza-bren (izalontamab brengitecan, BL-B01D1) in the List of Breakthrough Therapy Designations for Patients with Recurrent or Metastatic Biliary Tract Cancer Who Have Failed Prior Platinum-based Chemotherapy

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Filed with SSE · Stock code 688506 ·

Announcement on Voluntary Disclosure of the Inclusion of iza-bren (izalontamab brengitecan, BL-B01D1) in the List of Breakthrough Therapy Designations for Patients with Recurrent or Metastatic Biliary Tract Cancer Who Have Failed Prior Platinum-based Chemotherapy

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

View original source (Shanghai Stock Exchange)Company analysis

Earlier from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

All Sichuan Biokin Pharmaceutical Co., Ltd. Class A news releases